+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients



Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients



Japanese Journal of Cancer Research 86(1): 28-34



Sera were examined for the presence of antibody against E7 protein of human papillomavirus type 16 (HPV-16) by Western blot analysis using the bacterially derived unfused protein. The occurrence rates of anti-E7 antibody against HPV-16 were 14.1% (10/71) in cervical cancer patients, 0% (0/48) in cervical intraepithelial neoplasia patients, and 0% (0/41) in female non-malignant patients. Three patients (one with endometrial cancer, one with breast cancer, and one male patient with colon polyp) out of 115 patients with tumors in organs other than the cervix, had antibody against E7 protein of HPV-16. The serum antibody, once positive, could be detected for a long time after surgical removal of the cancers in all cases that could be followed up. HPV-16 DNA could be detected in 50% (13/26) of cervical cancer patients. Sixty-nine percent (9/13) of patients with HPV-16 DNA in cancers had the antibody and all the patients with stages II, III, and IV cervical cancer (8/8) harboring HPV-16 DNA showed the presence of the antibody against E7 protein of HPV-16. In contrast, only 20% (1/5) of cervical cancer patients with stage la or lb harboring HPV-16 DNA showed positive for the anti-E7 antibody in sera. These findings suggest that the presence of anti-E7 antibody in serum depends on the staging of cervical cancer and extent of HPV infection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009404610

Download citation: RISBibTeXText

PMID: 7737906

DOI: 10.1111/j.1349-7006.1995.tb02984.x


Related references

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Intervirology 38(3-4): 187-191, 1995

The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients. Journal of Virological Methods 62(1): 81-85, 1996

Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. Journal of Infectious Diseases 181(5): 1764-1767, 2000

Expression of human papillomavirus type 16 E7 protein by recombinant baculovirus and use for the detection of E7 antibodies in sera from cervical carcinoma patients. Journal Of Medical Virology. 40(1): 14-21, 1993

Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. Journal of Virology 74(6): 2888-2894, 2000

Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku Journal of Experimental Medicine 170(2): 113-121, 1993

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Research 66(23): 11120-4, 2006

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. Journal of Virology 73(7): 5402-5410, 1999

Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. Journal of Virology 77(9): 5464-5474, 2003

A research for the relationship between human papillomavirus and human uterine cervical carcinoma. II. Molecular genetic and ultrastructural study on the transforming activity of recombinant retrovirus containing human papillomavirus type 16 subgenomic sequences. Journal of Cancer Research and Clinical Oncology 117(5): 460-472, 1991

A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Human Gene Therapy 14(15): 1389-1399, 2003

Detection of E2 gene polymorphism of human papillomavirus type 16 in patients with cervical lesions and cervical cancer. Nan Fang Yi Ke Da Xue Xue Bao 32(10): 1503-1506, 2012

Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. Journal Of Medical Virology. 45(3): 342-347, 1995

The prognostic role of serologic testing for antibody production against human papillomavirus type 16 E6 and E7 oncogenes in cervical cancer. Gynecologic Oncology 56(1): 138, 1995

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 374(1773): 20180295, 2019